Evaluating a new injection for female contraception without estrogen
PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION - UC DAVIS
['FUNDING_OTHER'] · UNIVERSITY OF CALIFORNIA AT DAVIS · NIH-11042024
This study is testing a new long-lasting birth control shot called levonorgestrel butanoate, which is made for women, especially those who are overweight and at risk for blood clots, to see how well it works and if it's safe, making it easier for women to manage their contraception without needing to remember to take a pill every day.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA AT DAVIS (nih funded) |
| Locations | 1 site (DAVIS, UNITED STATES) |
| Trial ID | NIH-11042024 on ClinicalTrials.gov |
What this research studies
This research investigates a new long-acting injectable contraceptive called levonorgestrel butanoate (LB), designed specifically for women, particularly those who are obese and at risk for venous thromboembolism (VTE). The study aims to assess the pharmacokinetics and pharmacodynamics of LB to ensure its effectiveness and safety as an estrogen-free contraceptive option. By providing a method that does not require daily adherence, this injectable form could offer a more convenient and safer alternative for women seeking contraception. Participants will be involved in a clinical trial to gather data on the drug's performance and potential benefits.
Who could benefit from this research
Good fit: Ideal candidates for this research are women, particularly those who are obese and seeking effective contraception without the risks associated with estrogen.
Not a fit: Patients who are not seeking contraception or those who do not have concerns related to VTE may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more convenient contraceptive option for women, especially those at higher risk for VTE.
How similar studies have performed: Previous research has shown success with other long-acting contraceptive methods, indicating potential for this novel approach.
Where this research is happening
DAVIS, UNITED STATES
- UNIVERSITY OF CALIFORNIA AT DAVIS — DAVIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MICHAEL, CREININ — UNIVERSITY OF CALIFORNIA AT DAVIS
- Study coordinator: MICHAEL, CREININ
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.